At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST6
In Brief
A Phase 2 clinical trial evaluating Atomoxetine and Placebo for Vasovagal Syncope. Completed, enrolled 57 participants across 1 site.
Detailed Summary
Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasovagal Syncope
CountriesCanada
CollaboratorsCardiac Arrhythmia Network of Canada
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedJul 2015
Primary CompletionJan 2018
Study CompletionMar 2018
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartJul 1, 2015
Primary CompletionJan 1, 2018
Study CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.0 years ago
Interventions
Atomoxetinedrug
40mg PO the night before and the morning of the study tilt table test.
Placebodrug
oral placebo capsule designed to blind the atomoxetine intervention